[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)
- Registry ID
- 2025-521324-29-00
- Source registry
- CTIS
- Status
- Authorised
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- Odense University Hospital
- Enrollment
- 65
- Last update
- 2026-08-14
Conditions
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Diseases [C] - Neoplasms [C04]
- Primary breast cancer
Primary outcomes
Sensitivity, specificity, predictive values, and accuracy for primary staging and restaging breast cancer with [⁶⁸Ga]Ga-HKG301 PET/CT
Locations
Related clinical trials
- A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination with Cytarabine Injection Versus Placebo in Combination with Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects with Refractory/Relapsed Acute Myeloid Leukemia
- LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu FAP 2286 in Participants with an Advanced Solid Tumor
- A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
- Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
- A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2
- C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER
View on source registry